GlassScriptPhysician profile
Bradley A Barter
NPI 1235207077
$10,682.52
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $1,552 · 2021: $2,412 · 2022: $1,811 · 2023: $626 · 2024: $3,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,436 · Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,435.66 |
| Food and Beverage | $2,148.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $3,726.98 | 2019-2024 | Persona, Mymobility Platform, Gel-One Cross-Linked Hyaluronate |
| Stryker Corporation | $1,959.36 | 2019-2023 | Mako, Triathlon |
| Arthrex, INC. | $1,618.00 | 2021 | |
| Treace Medical Concepts, INC. | $1,450.23 | 2022-2024 | |
| Smith+Nephew, INC. | $451.83 | 2021-2024 | Stravix, Grafix Pl, Stravix Pl |
| Mid-Atlantic Surgical Systems, LLC | $321.90 | 2021 | |
| Sanara Medtech INC. | $180.86 | 2022 | |
| Bioventus LLC | $160.84 | 2023-2024 | Durolane, Exogen Ultrasound Bone Healing System, Durolane |
| Novastep INC. | $134.43 | 2021 | |
| Endo Pharmaceuticals INC. | $112.07 | 2020-2022 | |
| Organogenesis INC. | $104.09 | 2023-2024 | Puraply, Nushield, Puraforce |
| Globus Medical, INC. | $93.39 | 2019 | |
| Innovation Technologies INC | $72.20 | 2022 | |
| Heron Therapeutics, INC. | $49.61 | 2019 | |
| Maxx Health INC | $43.00 | 2024 | Summa Ortho Optossol |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $41.14 | 2020 | |
| Baudax Bio INC. | $36.70 | 2020-2022 | |
| Crossroads Extremity Systems, LLC | $27.64 | 2021 | |
| Glaxosmithkline, LLC. | $24.93 | 2019 | |
| Axogen | $24.71 | 2022 | |
| Celularity INC. | $19.00 | 2019 | |
| Amniox Medical, INC. | $16.48 | 2020 | |
| Amgen INC. | $13.13 | 2024 | Krystexxa |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Barter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.